1,2,4-Triazolo [4,3-A] Pyridine Derivatives and Their Use For The Treatment of Prevention of Neurological and Psychiatric Disorders
申请人:JANSSEN PHARMACEUTICALS, INC.
公开号:US20150141403A1
公开(公告)日:2015-05-21
The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I)
wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.
本发明涉及一种新型的三唑并[4,3-a]吡啶衍生物,其化学式为(I),其中所有基团如权利要求所定义。本发明的化合物是代谢型谷氨酸受体亚型2(“mGluR2”)的正向变构调节剂,可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型受体亚型mGluR2的疾病。本发明还涉及包含这种化合物的制药组合物、制备这种化合物和组合物的过程,以及使用这种化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病的方法。